A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Daclizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics
- Acronyms SELECTION
- Sponsors Biogen Idec
- 28 Apr 2017 Results examining degree of return of disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) following discontinuation of treatment with daclizumab HYP (daclizumab) in SELECT/SELECTION Studies presented at the 69th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Results (pooled analysis of SELECT and SELECTION studies, n = 73) assessing effects of daclizumab HYP 150mg on total and differential lymphocyte populations presented at the 68th Annual Meeting of the American Academy of Neurology.
- 20 Apr 2016 A post-hoc analysis of results from SELECT and SELECTION trials presented at the 68th Annual Meeting of American Academy of Neurology (AAN)2016, according to a Biogen media release.